Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14816387 | 0.98 | CYP2C19 (0.46) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| SCHEMBL30934054 | 0.98 | CYP2C19 (0.46) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| SCHEMBL9253225 | 0.98 | CYP2C19 (0.46) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| SCHEMBL9365663 | 0.98 | CYP2C19 (0.46) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| SCHEMBL9256535 | 0.98 | CYP2C19 (0.46) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| SCHEMBL9366283 | 0.98 | CYP2C19 (0.46) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| SCHEMBL4750570 | 0.92 | — | — | |
| SCHEMBL28438321 | 0.90 | APP (0.44) | APPCYP2C19CYP1A2CYP2D6MAPT | |
| Benzene SCHEMBL27390163 | 0.83 | EPHX2 (0.42) | CYP2C19CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL5708005 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-112079866-B | ALK protein regulator and anti-tumor application thereof | 上海科技大学 | 2024-05-31 | — | — | CN | disclosed |
| US-11535647-B2 | Peptide purification method using sulfonate compound | NAGASE & CO., LTD. (JP) | 2022-12-27 | — | — | US | disclosed |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | NAGASE & CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| WO-2022017442-A1 | BIFUNCTIONAL PROTEIN DEGRADATION-TARGETED CHIMERA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2022-01-27 | — | — | WO | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6150303-A | Substituted 3-phenylisoxazolines | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
| US-5622913-A | CONTROLLING PLANT GROWTH | AMERICAN CYANAMID COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5599773-A | (2-imidazolin-2-yl) fused heteropyridine compounds and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1997-02-04 | — | — | US | disclosed |
| US-5536702-A | (2-imidazolin-2-yl) fused heteropyridine compounds and use of said compounds as herbicidal agents | AMERICAN CYANAMID CO. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5536839-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5534483-A | (2-imidazolin-2-yl) fused heteropyridine compounds intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534485-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534484-A | (2-imidazolin-2-yl)fused heteropyridine compounds intermediates for the preparation of and use of said compounds and herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5532207-A | CONTROL OF MONO- AND DI-COTYLEDONOUS ANNUAL, PERENNIAL AND AQUATIC PLANTS; PRE- AND POST-EMERGENCE USE | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5510319-A | PYRROLO-2,3-B-PYRIDINYL DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5252538-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0227932-B1 | NOVEL FUSED PYRIDINE COMPOUNDS, INTERMEDIATES FOR THE PREPARATION OF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0227932-A1 | Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | APP 3066/4885CYP2C19 415/4885CYP1A2 32/4885 |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | VIP, IAPP, RPS27A | APP 269/4885CYP2C19 4307/4885CYP1A2 4855/4885 |
| US-11535647-B2 | Peptide purification method using sulfonate compound | VIP, IAPP, RPS27A | APP 269/4885CYP2C19 4307/4885CYP1A2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.